Fondazione Toscana Gabriele Monasterio
- Address
- Via Trieste 41, 56126 Pisa, Italy
Fondazione Toscana Gabriele Monasterio - Advanced Cardiac Research Center
Fondazione Toscana Gabriele Monasterio is a leading medical research institution specializing in cardiovascular diseases and advanced cardiac diagnostics. The center demonstrates particular expertise in rare and complex cardiac conditions, with a strong focus on cardiomyopathies and amyloid heart disease. Their research portfolio encompasses both innovative therapeutic interventions and cutting-edge diagnostic imaging techniques, including advanced PET-CT imaging for cardiac pathology assessment.
- Cardiac amyloidosis (AL and ATTR-CM) diagnosis and treatment, including novel PET imaging tracers and disease-modifying therapies
- Hypertrophic cardiomyopathy (HCM) in both obstructive and non-obstructive forms, evaluating next-generation cardiac myosin inhibitors
- Pulmonary arterial hypertension (PAH) management with advanced endothelin receptor antagonists and novel therapeutic agents
- Heart failure with preserved ejection fraction (HFpEF) and cardiovascular disease prevention strategies
The center's comprehensive research program extends from early disease prevention in asymptomatic genetic carriers to advanced therapeutic trials in symptomatic patients. Notable areas of investigation include genetic cardiomyopathies such as BAG3-associated dilated cardiomyopathy, acute myocarditis treatment optimization, and sex-specific differences in heart failure management. The institution actively participates in international multicenter trials evaluating novel pharmacological agents, gene therapies, and precision medicine approaches for cardiovascular conditions, with particular emphasis on improving patient-reported outcomes and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondazione Toscana Gabriele Monasterio
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.